Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
NCT02832037
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
509
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
BI 425809 dose 1
DRUG:
BI 425809 dose 2
DRUG:
BI 425809 dose 3
DRUG:
BI 425809 dose 4
DRUG:
Placebo
Sponsor
Boehringer Ingelheim